NM_000069.3:c.2673C>T

Variant summary

Our verdict is Benign. Variant got -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BA1

The NM_000069.3(CACNA1S):​c.2673C>T​(p.Ser891Ser) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00778 in 1,611,918 control chromosomes in the GnomAD database, including 335 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.027 ( 154 hom., cov: 32)
Exomes 𝑓: 0.0058 ( 181 hom. )

Consequence

CACNA1S
NM_000069.3 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:12

Conservation

PhyloP100: -6.39
Variant links:
Genes affected
CACNA1S (HGNC:1397): (calcium voltage-gated channel subunit alpha1 S) This gene encodes one of the five subunits of the slowly inactivating L-type voltage-dependent calcium channel in skeletal muscle cells. Mutations in this gene have been associated with hypokalemic periodic paralysis, thyrotoxic periodic paralysis and malignant hyperthermia susceptibility. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -19 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.46).
BP6
Variant 1-201066301-G-A is Benign according to our data. Variant chr1-201066301-G-A is described in ClinVar as [Benign]. Clinvar id is 254819.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-201066301-G-A is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-6.39 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.0793 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CACNA1SNM_000069.3 linkc.2673C>T p.Ser891Ser synonymous_variant Exon 21 of 44 ENST00000362061.4 NP_000060.2 Q13698
CACNA1SXM_005245478.4 linkc.2673C>T p.Ser891Ser synonymous_variant Exon 21 of 43 XP_005245535.1 B1ALM3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CACNA1SENST00000362061.4 linkc.2673C>T p.Ser891Ser synonymous_variant Exon 21 of 44 1 NM_000069.3 ENSP00000355192.3 Q13698

Frequencies

GnomAD3 genomes
AF:
0.0271
AC:
4124
AN:
151932
Hom.:
153
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0816
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0225
Gnomad ASJ
AF:
0.0184
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00499
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.0190
Gnomad NFE
AF:
0.00372
Gnomad OTH
AF:
0.0293
GnomAD3 exomes
AF:
0.0109
AC:
2729
AN:
249768
Hom.:
72
AF XY:
0.00966
AC XY:
1306
AN XY:
135158
show subpopulations
Gnomad AFR exome
AF:
0.0850
Gnomad AMR exome
AF:
0.0136
Gnomad ASJ exome
AF:
0.0165
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00624
Gnomad FIN exome
AF:
0.0000499
Gnomad NFE exome
AF:
0.00374
Gnomad OTH exome
AF:
0.0153
GnomAD4 exome
AF:
0.00576
AC:
8410
AN:
1459868
Hom.:
181
Cov.:
32
AF XY:
0.00568
AC XY:
4128
AN XY:
726334
show subpopulations
Gnomad4 AFR exome
AF:
0.0869
Gnomad4 AMR exome
AF:
0.0142
Gnomad4 ASJ exome
AF:
0.0170
Gnomad4 EAS exome
AF:
0.0000756
Gnomad4 SAS exome
AF:
0.00625
Gnomad4 FIN exome
AF:
0.000136
Gnomad4 NFE exome
AF:
0.00268
Gnomad4 OTH exome
AF:
0.0121
GnomAD4 genome
AF:
0.0272
AC:
4130
AN:
152050
Hom.:
154
Cov.:
32
AF XY:
0.0264
AC XY:
1962
AN XY:
74328
show subpopulations
Gnomad4 AFR
AF:
0.0816
Gnomad4 AMR
AF:
0.0225
Gnomad4 ASJ
AF:
0.0184
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00458
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00371
Gnomad4 OTH
AF:
0.0290
Alfa
AF:
0.0146
Hom.:
26
Bravo
AF:
0.0326
Asia WGS
AF:
0.00577
AC:
21
AN:
3478
EpiCase
AF:
0.00463
EpiControl
AF:
0.00593

ClinVar

Significance: Benign
Submissions summary: Benign:12
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Malignant hyperthermia, susceptibility to, 5 Benign:3
Apr 11, 2023
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Feb 05, 2024
All of Us Research Program, National Institutes of Health
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Sep 16, 2022
Color Diagnostics, LLC DBA Color Health
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not specified Benign:2
-
PreventionGenetics, part of Exact Sciences
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Mar 17, 2016
GeneDx
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Hypokalemic periodic paralysis, type 1 Benign:2
Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Apr 11, 2023
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not provided Benign:2
Dec 04, 2017
Athena Diagnostics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: not provided

- -

Congenital myopathy 18 Benign:1
Apr 11, 2023
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Thyrotoxic periodic paralysis, susceptibility to, 1 Benign:1
Apr 11, 2023
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Malignant hyperthermia, susceptibility to, 5;C3714580:Hypokalemic periodic paralysis, type 1 Benign:1
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.46
CADD
Benign
0.48
DANN
Benign
0.63

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs16847623; hg19: chr1-201035429; COSMIC: COSV62939819; API